Cyto Pulse Sciences, Inc., the Karolinska Hospital/Institutet and SMI Receive Approval from the Swedish Medical Products Agency to Start a Clinical Trial Evaluating a CEA-based Vaccine in Patients with Colorectal Cancer.
11/4/2009 11:04:53 AM
GLEN BURNIE, Md.--(BUSINESS WIRE)--Cyto Pulse Sciences, a leading producer of electric field based, intradermal DNA Vaccine delivery systems, today announced approval by the Swedish regulatory authorities to begin a Phase I/II study of DNA vaccination in patients with colorectal cancer. The trial will investigate the safety of a DNA vaccine delivered by the Derma Vax™ intradermal electroporation system. The vaccine, which encodes Carcinoembryonic Antigen (CEA), was developed jointly by the Swedish Institute for Infectious Disease Control (SMI)/Karolinska Institutet (KI) and Cyto Pulse.